html templates

WHO WE ARE

The leaders of SIGLA SCIENCES have decades of experience in pharma, biotech, and diagnostics, and have worked on dozens of product launches in oncology, specialty, and rare disease areas. Our team has also helped companies shape cross-portfolio marketing strategies, build commercial revenue forecasts, develop in-depth policy impact assessments, and create compelling payer value propositions for specialty products.

Many consultants offer advice, but few can transform it into executable strategies forged by real-world leadership experience. We bridge that gap, translating high-level strategies into messaging, creative tactics, digital plans, and operational roadmaps to win in the market—all at a fraction of typical agency costs through our lean, distributed model. We understand that the strategies and tactics that previously led to blockbuster products are insufficient to guarantee access, market reach, and a strong value proposition in today's more challenging and sophisticated payer and provider landscape.

Our hands-on leadership team has walked in your shoes, having held client-side roles. We understand the importance of managing resources judiciously, delivering high-quality results on time, and fostering internal alignment. 

ABOUT OUR LEADERSHIP TEAM

Our leadership team has previously worked in the life sciences industry ranging from digital health startups and policy organizations to precision medicine, NCI-designated cancer centers, and big pharma. Our CVs include the following past employers: Genentech, The James Cancer Center at The Ohio State University, City of Hope, National Comprehensive Cancer Network, Roche Pharma UK, Caris Life Sciences, Catalia Health, Morrison & Foerster LLP, the Association of State and Territorial Health Officials, and NASA. Our degrees are from MIT, Georgia Tech, the University of Texas, Princeton, The University of Oxford, the London School of Economics, West Virginia University, and The Ohio State University. Our team of consultants, creatives, and analysts include alumni of McKinsey, Bristol Myers Squibb, Accenture, Ferring Pharmaceuticals, J&J, and the University of Cambridge.

A PART OF THE SUMIS PARTNERS ALLIANCE

Sigla Sciences is part of Sumis Partners, an alliance of owner-operated life sciences professional services firms that joined forces in 2025 to bring best-in-class, outcomes-oriented expertise to clients across the biopharma, diagnostics, and devices sectors. This alliance allows Sigla Sciences to leverage a broader network of experts and execution-focused specialists to deliver larger engagements and end-to-end launch preparedness for our clients.

Jen Hinkel

FOUNDER AND PRESIDENT: JEN HINKEL, MSC

Jen Hinkel is an oncology market access and health economics leader with experience in consulting, global pharma and biotech, health policy, and health care startups. She has held management and executive roles at companies including National Comprehensive Cancer Network (NCCN), Roche UK, Roche Argentina, Genentech, and Caris Life Sciences.

Previously, she was a Senior Partner at McGivney Global Advisors, where she built an oncology and specialty therapeutics consulting practice focused on market access, HEOR, and launch readiness, supporting dozens of new drugs and indication expansions coming to market over a five-year tenure. Jen held pricing, distribution, oncology marketing, and key hospital account sales roles at Roche and Genentech in the US, Latin America, and United Kingdom. She also led financial impact assessment for the Affordable Care Act and Medicare reimbursement in Genentech's Industry Analytics group, for which she received the Genentech ACE Award. Prior to joining the biopharmaceutical industry, Ms. Hinkel held roles at National Comprehensive Cancer Network (NCCN), the Association for State and Territorial Health Officials (ASTHO), and as a researcher for a member of the UK House of Lords. She presently sits on the board of several early-stage technology and science companies and is an advisor to multiple patient advocacy groups.

She holds degrees from the Georgia Institute of Technology (BS International Affairs) and the London School of Economics (MSc International Health Policy), and is DPhil candidate in Evidence Based Health Care at the University of Oxford. She has lectured in Health Systems and Health Economics at Penn State University and Arcadia University, holds patents in health care technology, and has published numerous articles and abstracts related to market access, HEOR, and health services research. As a survivor of Stage III Hodgkin Lymphoma, Ms. Hinkel has a special interest in oncology innovation. To support the broader survivor and oncology community, Ms. Hinkel founded Resilience Racing, the first all-cancer-survivor sailing team, and also was a founder of the 40 Under 40 in Cancer awards program.